Building on the success of the inaugural awards, Texas A&M Innovation has recently completed the second round of funding for its Translational Investment Fund (TIF), a program that provides investments into the development of disclosed technologies toward commercially relevant ends. Faculty and staff inventors may apply for investments of up to $75,000 to support year-long projects.
The second funding cycle for the TIF program kicked off this past summer, drawing in submissions from more than 16 different departments across campus. This round of investments will have an additional exciting new opportunity in front of them as Texas A&M Innovation teams up with the Aggie Angel Network to funnel promising TIF-funded A&M technologies into a technology showcase event.
The first of three investments this fall was awarded to support a project on a novel CAR-T cell therapy for liver cancer, led by Dr. Xiaotong Song. Dr. Song is with the Center for Infectious & Inflammatory Diseases in the Institute of Biosciences & Technology.
A second investment was made to support a project on Cobalt(III) Chirality sensing agents, led by Dr. John Gladysz of the Department of Chemistry in the College of Science.
Lastly, a third investment was made to support a project on glycoengineering and in vivo evaluation of anti-CD20 monoclonal antibody drug candidates, led by Dr. Karruppiah Chockalingam of the Department of Microbial Pathogenesis & Immunology in the College of Medicine.
Congratulations to the Fall 2021 awardees; we look forward to seeing the successful advancements of these technologies in the future.
Learn more about the Translational Investment Fund.